Personalis Pre-Paid Expenses 2018-2025 | PSNL
Personalis pre-paid expenses from 2018 to 2025. Pre-paid expenses can be defined as a current asset created by prepayment of costs and expenses for which the benefits will occur at a future date.
Personalis Annual Pre-Paid Expenses
(Millions of US $) |
| 2024 |
$4 |
| 2023 |
$4 |
| 2022 |
$7 |
| 2021 |
$7 |
| 2020 |
$5 |
| 2019 |
$3 |
| 2018 |
$2 |
| 2017 |
$0 |
Personalis Quarterly Pre-Paid Expenses
(Millions of US $) |
| 2025-03-31 |
$5 |
| 2024-12-31 |
$4 |
| 2024-09-30 |
$5 |
| 2024-06-30 |
$4 |
| 2024-03-31 |
$5 |
| 2023-12-31 |
$4 |
| 2023-09-30 |
$6 |
| 2023-06-30 |
$5 |
| 2023-03-31 |
$8 |
| 2022-12-31 |
$7 |
| 2022-09-30 |
$8 |
| 2022-06-30 |
$6 |
| 2022-03-31 |
$6 |
| 2021-12-31 |
$7 |
| 2021-09-30 |
$8 |
| 2021-06-30 |
$9 |
| 2021-03-31 |
$6 |
| 2020-12-31 |
$5 |
| 2020-09-30 |
$5 |
| 2020-06-30 |
$3 |
| 2020-03-31 |
$3 |
| 2019-12-31 |
$3 |
| 2019-09-30 |
$4 |
| 2019-06-30 |
$2 |
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2018-06-30 |
|
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.431B |
$0.085B |
|
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
|
